MA54960A - Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine - Google Patents

Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Info

Publication number
MA54960A
MA54960A MA054960A MA54960A MA54960A MA 54960 A MA54960 A MA 54960A MA 054960 A MA054960 A MA 054960A MA 54960 A MA54960 A MA 54960A MA 54960 A MA54960 A MA 54960A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrimidine
amine derivative
amine
derivative
Prior art date
Application number
MA054960A
Other languages
English (en)
Inventor
Hirokazu Fuchida
Shoki Hara
Hidefumi Kasuga
Yu KOBAYAKAWA
Takashi Mizutani
Yoshio Ogino
Fuyuki Yamamoto
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA54960A publication Critical patent/MA54960A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054960A 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine MA54960A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019025844 2019-02-15

Publications (1)

Publication Number Publication Date
MA54960A true MA54960A (fr) 2021-12-22

Family

ID=72044229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054960A MA54960A (fr) 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Country Status (14)

Country Link
US (1) US11786534B2 (fr)
EP (1) EP3925669A4 (fr)
JP (1) JP6960064B2 (fr)
KR (1) KR102645237B1 (fr)
CN (1) CN113453764B (fr)
AU (1) AU2020221744B2 (fr)
BR (1) BR112021015813A2 (fr)
CA (1) CA3130049C (fr)
MA (1) MA54960A (fr)
MX (1) MX2021009752A (fr)
PH (1) PH12021551957A1 (fr)
SG (1) SG11202108648TA (fr)
TW (1) TWI828861B (fr)
WO (1) WO2020166680A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900490B2 (ja) * 2022-04-22 2026-08-04 大鵬薬品工業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体の結晶
TW202400139A (zh) 2022-04-22 2024-01-01 日商大鵬藥品工業股份有限公司 ７Ｈ－吡咯［２，３－ｄ〕嘧啶－４－胺衍生物之製造方法
EP4784119A1 (fr) * 2023-09-29 2026-08-05 Taiho Pharmaceutical Co., Ltd. Cristaux de dérivés de 7h-pyrrolo [2,3-d] pyrimidin-4-amine
CN122438686A (zh) 2023-12-13 2026-07-21 大鹏药品工业株式会社 以N－（4－（4－氨基－6－乙炔基－5－（喹啉－3－基）－7H－吡咯并［2,3－d］嘧啶－7－基）双环［2.2.1］庚烷－1－基）－5－甲基吡嗪－2－甲酰胺或其盐为有效成分的脑转移性肿瘤治疗剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
US20080299113A1 (en) 2005-12-19 2008-12-04 Arnold Lee D Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
KR20150084923A (ko) * 2012-11-15 2015-07-22 파마시클릭스, 인코포레이티드 키나제 억제제로서의 피롤로피리미딘 화합물
EP3145512B1 (fr) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
AU2017350440B2 (en) 2016-10-31 2023-01-12 Taiho Pharmaceutical Co., Ltd. Selective inhibitor of exon 20 insertion mutant EGFR

Also Published As

Publication number Publication date
CN113453764A (zh) 2021-09-28
TWI828861B (zh) 2024-01-11
JP6960064B2 (ja) 2021-11-05
US11786534B2 (en) 2023-10-17
KR20210116598A (ko) 2021-09-27
US20220160719A1 (en) 2022-05-26
PH12021551957A1 (en) 2022-05-23
EP3925669A1 (fr) 2021-12-22
KR102645237B1 (ko) 2024-03-07
WO2020166680A1 (fr) 2020-08-20
TW202045509A (zh) 2020-12-16
CA3130049C (fr) 2024-04-16
CN113453764B (zh) 2024-04-16
AU2020221744A1 (en) 2021-09-23
AU2020221744B2 (en) 2022-06-23
MX2021009752A (es) 2021-09-08
SG11202108648TA (en) 2021-09-29
CA3130049A1 (fr) 2020-08-20
BR112021015813A2 (pt) 2021-10-13
JPWO2020166680A1 (ja) 2021-11-04
EP3925669A4 (fr) 2022-10-26

Similar Documents

Publication Publication Date Title
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
IL276802B1 (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
EP3980010A4 (fr) Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
HUE051424T2 (hu) RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
ZA201802842B (en) [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
ZA202105338B (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
IL290445A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
LT3820872T (lt) Pirolo[1,2-b]piridazino dariniai
EP3744723A4 (fr) Composé macrocyclique de pyrazolo [1,5-a]pyrimidine substitué
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
EP3925669A4 (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
IL269214B (en) Novel imidazo[5,4-c]quinoline derivatives as lrrk2 inhibitors
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
EP3196199A4 (fr) N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase
DK3459953T3 (da) Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
EP3640253A4 (fr) Dérivé de 6h-thiéno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazépine
EP3903788A4 (fr) Composé macrocyclique de pyrazolo[1,5-a] pyrimidine
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok